TRYbeCA-1 Phase 3 Trial:
- More than 75% of the planned~500 patients enrolled
- Fast-Drack designation granted by U.S. FDA
- Trial to continue as planned after third independent safety review
- Interim superiority analysis expected around year-end and final analysis in 2H of 2021
Cash position of € 58.6 million ($64.6 million) at the end of the first quarter 2020
ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update